



**TRIDENT LIFELINE LIMITED**  
(Formerly Trident Lifeline Private Limited)

CIN No. : L51909GJ2014PLC078227

GST No. : 24AAECT8906D1ZG

**Date: December 23, 2024**

<b>BSE Limited</b> <b>14<sup>th</sup> Floor, P. J. Towers,</b> <b>Dalal Street, Fort,</b> <b>Mumbai – 400001.</b>	<b>Stock ID: TLL</b> <b>Scrip Code: 543616</b>
--	---

**Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') – Acquiring 51% stake and making a Subsidiary**

Dear Sir/Ma'am,

Pursuant to Regulation 30 of the SEBI Listing Regulations, we would like to inform that the Board of Directors of the Company had proposed to acquire 51 % of share of **TRIDENT MEDIQUIP LIMITED ("TMQL")** (CIN: U33309GJ2019PLC110421) from existing shareholders of the Company and making TMQL as a subsidiary of the Company.

Pursuant to BSE Notice No. 20230714-34 dated July 14, 2023, occurrence of the above event/information is on December 23, 2024 at 07:20 p.m.

Further, the information under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed herewith.

The board meeting was commenced at 07:20 p.m. and concluded at 07:50 p.m.

Thanking you,  
**For Trident Lifeline Limited**

**NIKITA SHARMA**  
**COMPANY SECRETARY AND COMPLIANCE OFFICER**  
**M. NO.: A60595**

**Information under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.**

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	<p><b>TRIDENT MEDIQUIP LIMITED (CIN: U33309GJ2019PLC110421)</b> Company incorporated under the provisions of the Companies Act, 2013, having its Registered Office in Surat, Gujarat.</p> <p><b>Capital Details:</b>  <b>Authorized Share Capital:</b> Rs. 8,00,00,000 /- divided into 80,00,000 Equity Shares of Rs.10/- each</p> <p><b>Paid-up Share Capital:</b> Rs. 7,78,00,000/- divided into 77,80,000 Equity Shares of Rs.10/- each</p> <p><b>Turnover:</b> Rs. 20,58,08,887/-</p>
2	whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	<p><b>Yes,</b> TRIDENT MEDIQUIP Limited (TMQL), a public Limited Company in which Mr. Hardik Jigishkumar Desai, Amit Bhupendra Halvawala and Mr. Chetan Chandrakant Jariwala (director’s Relative) are member cum Director and all of above are part of promoters/promoter group/board of acquiring Company i.e being Trident Lifeline Limited (The Company), have an interest in the entity being acquired (TMQL).</p> <p>The transaction is being undertaken on an arm's length basis.</p>
3	Industry to which the entity being acquired belongs	Pharmaceuticals Industry
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	This acquisition would allow the company to partner with the leading and fast-growing market of medical & surgical and/or diagnostic equipments, along with pharmaceuticals and allied products.

**TRIDENT LIFELINE LIMITED**

(Formerly Trident Lifeline Private Limited)

5	Brief details of any governmental or regulatory approvals required for the acquisition.	The acquisition is within the overall limit approved by the Shareholders of the Company under Section 186 of the Companies Act, 2013.
6	Indicative time period for completion of the acquisition	Approx. One Month
7	Consideration - whether cash consideration or share swap and details of the same;	Acquisition of shares is by way of Cash
8	Cost of acquisition or the price at which the shares are acquired;	Rs 10/- per share (face value)
9	Percentage of shareholding / control acquired and / or number of shares acquired;	<b>Pre-acquisition holding:</b> NIL  <b>Post-acquisition holding (Proposed):</b> 39,67,800 equity shares of Rs 10/- amounting of Rs. 3,96,78,000/- constituting 51% equity stake
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<b>Date of incorporation:</b> October 19, 2019  <b>Product/line of business:</b> Pharmaceuticals and Chemical Industry  <b>Last 3 years' turnover:</b> Financial year 2021-22: 35,08,25,152.94/- Financial year 2022-23: 28,77,39,633.10/- Financial year 2023-24- Rs. 20,58,08,887/-  <b>Presence of entity:</b> India